{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=54", "query": { "condition": "Multiple Myeloma", "page": 54 }, "page_size": 10 }, "pagination": { "page": 54, "page_size": 10, "total_count": 2319, "total_pages": 232, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=55&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=53&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T15:43:53.403Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04977024", "title": "SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Infection", "Hematopoietic and Lymphoid System Neoplasm", "Leukemia", "Lymphoma", "Plasma Cell Myeloma" ], "interventions": [ { "name": "COVID-19 Vaccine", "type": "BIOLOGICAL" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "GeoVax, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2021-09-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 6, "location_summary": "Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04977024" }, { "nct_id": "NCT03687125", "title": "Tinostamustine Conditioning and Autologous Stem Cell", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma in Relapse", "Multiple Myeloma Progression", "Multiple Myeloma With Failed Remission" ], "interventions": [ { "name": "Tinostamustine", "type": "DRUG" }, { "name": "Autologous Stem Cell Transplant (ASCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mundipharma-EDO GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 6, "start_date": "2018-10-15", "completion_date": "2019-04-17", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Kansas City, Kansas • New York, New York + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03687125" }, { "nct_id": "NCT02492750", "title": "Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Indolent Plasma Cell Myeloma", "Plasma Cell Myeloma", "Smoldering Plasma Cell Myeloma" ], "interventions": [ { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2016-04", "completion_date": "2019-09-13", "has_results": true, "last_update_posted_date": "2020-03-25", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02492750" }, { "nct_id": "NCT00897910", "title": "Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2008-04", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2016-01-11", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897910" }, { "nct_id": "NCT00002810", "title": "High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "melphalan", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": null, "start_date": "1996-05", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2010-10-01", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002810" }, { "nct_id": "NCT05714839", "title": "A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab", "type": "DRUG" }, { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2023-06-14", "completion_date": "2028-08-03", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 11, "location_summary": "Bullhead City, Arizona • Los Angeles, California • Pembroke Pines, Florida + 8 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05714839" }, { "nct_id": "NCT06679101", "title": "A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma", "Newly Diagnosed Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2024-12-16", "completion_date": "2031-04-28", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 30, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 26 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679101" }, { "nct_id": "NCT00884312", "title": "A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Solid Tumors" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2009-04-09", "completion_date": "2017-05-17", "has_results": true, "last_update_posted_date": "2018-05-14", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00884312" }, { "nct_id": "NCT05462639", "title": "Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab (PF-06863135)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 33, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462639" }, { "nct_id": "NCT00002657", "title": "SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 20, "start_date": "1995-05", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-11-02T15:43:53.403Z", "location_count": 86, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002657" } ] }